To further explore the impact of CXCR5 and LAG‐3 expression on patient outcomes, DLBCL patients were stratified into high‐CXCR5/low‐CXCR5 and high‐LAG‐3/low‐LAG‐3 groups based on median expression values: CXCR5+ CD8+ T (%) = 6.45% and LAG‐3+ CD8+ T (%) = 6.64%. The gene discussed is CD8A; the disease is diffuse large B-cell lymphoma.